Endogenex vs Doximity
Side-by-side comparison of AI visibility scores, market position, and capabilities
Endogenex develops the ReCET System, a catheter-based endoscopic device that remodels duodenal tissue to treat Type 2 diabetes without surgery; raised $25M Series B in 2024; completed European clinical trials with positive glycemic outcomes;
About
Endogenex is a medical device company headquartered in New Hope, Minnesota, developing endoscopic therapies for metabolic diseases. Its flagship product, the ReCET (Re-Cellularization via Electroporation Therapy) System, uses a catheter-based approach to deliver controlled electrical pulses to the duodenal lining. This non-surgical procedure remodels the duodenal epithelium — the tissue layer believed to play a key role in insulin resistance and glucose regulation — restoring more normal metabolic signaling without removing or bypassing anatomy.
Doximity (NYSE: DOCS), professional network for US physicians with 2M+ verified clinicians; telehealth, medical news, and career tools monetized via pharmaceutical digital marketing.
About
Doximity is a professional network and digital health platform purpose-built for licensed physicians and other healthcare professionals in the United States. With more than two million verified clinicians on the platform — representing the majority of practicing US physicians — Doximity has established itself as the dominant professional network for doctors, providing identity-verified peer connections, specialty-specific news feeds, medical journal access, and career management tools including a physician job board and CV builder. The verification layer distinguishes Doximity from general professional networks and makes it the standard reference for confirming physician credentials and contact information across the healthcare industry.
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Capabilities
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.